Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00034268 | A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer | PHASE3 | COMPLETED | - | — | — | Mar 1, 2002 | - | Jul 19, 2006 | 105 | United States, Argentina +19 |
| NCT00042679 | A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. | PHASE2 | COMPLETED | - | — | — | Jun 1, 2002 | - | Jul 19, 2006 | 11 | United States |
| Name | Type | Description |
|---|---|---|
| LY900003 | DRUG | - |
| Gemcitabine | DRUG | - |
| Carboplatin | DRUG | - |
Inclusion Criteria: 1. Stage IIIB or IV non-small lung cancer 2. Able to visit the doctor's office 3. At least 18 years of age 4. Adequate kidney, adrenal, and liver function Exclusion Criteria: 1. Prior chemotherapy or biologic therapy for NSCLC 2. Central nervous system tumors 3. Pregnant or br...